Q-omics provides the consensus-scored HIF1AP1 profile across patient tissues and cancer cell-line models. HIF1AP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, HIF1AP1 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, HIF1AP1 RNA expression shows 5,943 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight READ, STAD, and KIRC as cancer lineages where HIF1AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIF1AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIF1AP1 survival associations across molecular data types. HIF1AP1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIF1AP1 RNA expression–survival associations across cancer types. High HIF1AP1 expression shows unfavorable associations in READ, ACC, KICH, GBM and KIRC, but favorable associations in UCS. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify READ as the clearest survival context for HIF1AP1 RNA expression.
This table summarizes HIF1AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for HIF1AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIF1AP1 shows lower tumor expression in THCA and higher tumor expression in STAD, COAD, BRCA and KICH. The STAD box plot shows higher HIF1AP1 RNA expression in tumor versus normal tissue (log2 FC = +0.385, t-test p = .001).
This table shows molecular features associated with HIF1AP1 in patient tissues and cancer cell lines. In patient samples, HIF1AP1 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
